Osteoporosis Mngmt

Posted on Feb 9, 2011 in Expired CME | 4 comments

Managing Your Patients With Osteoporosis

 

Program Overview

Diagnosis of osteoporosis is suboptimal leading to undertreatment of this disease. There is underrecognition of the risk for osteoporosis and deficient assessment of patients who are in need of evaluation. Nearly one-half of adults with osteoporosis remain untreated with pharmacologic therapy after sustaining a fracture. Underutilization of assessment tools such as dual X-ray absorptiometry (DXA) and the FRAX® calculator further contribute to this problem. Although guidelines for the diagnosis and management of patients with osteoporosis have been recently updated, some clinicians are not familiar with them, presenting challenges to the diagnosis and treatment of osteoporosis. 

Further complicating the management of osteoporosis is poor adherence to treatment recommendations. Persistence with therapy is problematic. Discontinuation of medication is not uncommon, even within a short timeframe of receiving a prescription. Moreover, many patients do not comply with treatment recommendations such as taking medication incorrectly or failing to fill prescriptions. Issues such as ineffective treatments to manage all patients with osteoporosis, inability to individualize treatment to a patient’s clinical profile and medical history, insufficient patient education, and inadequate cross-team communication are at the center of this problem.

This activity will feature case-based scenarios that illustrate how to use and interpret evaluation tools such as DXA and FRAX®. Case presentations will also be used to illustrate strategies to manage a diverse set of patients and approaches to increase patient compliance and persistence.

Learning Objectives

After completing this activity, the participant should be better able to

1. Utilize NOF consensus recommendations regarding risk evaluation and treatment for patients at risk or with osteoporosis
2. Develop clinical strategies for managing a diverse set of patients with osteoporosis

Accreditation/Designation Statement

Primary Care Network is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Primary Care Network designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience: This activity is targeted to all physicians and other healthcare professionals who treat patients with osteoporosis.

Release Date: February 9, 2011
Expiration Date: February 9, 2012

Medium: Choose between Online CME (slides/audio) or Podcast (audio only) at the bottom of the page

Acknowledgment of Commercial Support

This activity was developed from the live Best Practices in Primary Care™ program held in Charlotte, North Carolina, on December 4, 2010, and is funded by Amgen.

Method of Participation

To receive CME credit for this activity, participant must read the CME information (including the learning objectives and disclosures) and review the entire activity (slides and audio for the Online CME or audio for Podcast). After finishing the activity, participant must complete the post-test, evaluation, and all required personal information. To receive CME certificate, participant will need to pass the post-test with 70% accuracy or better.

Post-test and Evaluation

After completing this activity, participant should click on the Post-test button at the end of the activity. If participant receives less than 70% on the post-test, participant should return to the beginning of the activity to review the activity again. After successful completion of the post-test, participant will be asked to fill out an evaluation form and prompted to print the CME certificate. Participant should PLEASE be ready to print certificate at this time.

Statement of Disclosure and Independence

It is the policy of Primary Care Network (PCN) to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME’s Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest and Disclosure Policies that are designed to ensure that PCN sponsored educational activities are fair balanced, independent, evidence-based, and based on scientific rigor.

Primary Care Network’s Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external clinical reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.

The opinions, ideas, recommendations, and perspectives expressed in the accompanying presentations in this Primary Care Education activity are those of the activity authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations, or perspectives of their affiliated institutions, Primary Care Network, Primary Care Education, Advisory Boards and Consultants, or the activity’s commercial supporters.

Faculty and Disclosures

Jeffrey P. Levine, MD, MPH
Professor/Director of Women’s Health Programs
Department of Family Medicine
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Dr. Levine is on the advisory boards for Amgen, Novartis, and Wyeth. He also serves on the speaker’s bureau for Merck.

Kenneth G. Saag, MD, MSc
Jane Knight Lowe Professor of Medicine
Division of Clinical Immunology and Rheumatology
University of Alabama, Birmingham School of Medicine
Professor of Epidemiology
University of Alabama, Birmingham School of Public Health
Birmingham, Alabama

Dr. Saag is on the advisory board for Novartis. He serves on the speakers’ bureaus for Amgen, and Eli Lilly, is a consultant for Amgen, AstraZeneca, Eli Lilly, Merck, Novartis, Pfizer, and Takeda, and participates in research grants for Amgen, Eli Lilly, Merck, Novartis, sanofi-aventis, and Takeda.

Planning Committee and Disclosures

Susan L. Greenspan, MD
Professor of Medicine
Director, Osteoporosis Prevention and Treatment Center
University of Pittsburgh Medical School
Pittsburgh, Pennsylvania

Dr. Greenspan is on the advisory boards for Amgen, Eli Lilly, and Merck. She is a consultant for Amgen and Merck and participates in research grants for Eli Lilly.

Cheryl L. Lambing, MD
Assistant Clinical Professor
Department of Family Medicine
University of California, Los Angeles
Faculty, Ventura County Medical Center
Family Medicine Residency Program
Los Angeles, California

Dr. Lambing serves on the speakers’ bureaus for Amgen, Merck, and Medtronic.

Jeffrey P. Levine, MD, MPH
Professor/Director of Women’s Health Programs
Department of Family Medicine
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Dr. Levine is on the advisory boards for Amgen, Novartis, and Wyeth. He also serves on the speaker’s bureau for Merck.

Kenneth G. Saag, MD, MSc
Jane Knight Lowe Professor of Medicine
Division of Clinical Immunology and Rheumatology
University of Alabama, Birmingham School of Medicine
Professor of Epidemiology
University of Alabama, Birmingham School of Public Health
Birmingham, Alabama

Dr. Saag is on the advisory board for Novartis. He serves on the speakers’ bureaus for Amgen, and Eli Lilly; is a consultant for Amgen, AstraZeneca, Eli Lilly, Merck, Novartis, Pfizer, and Takeda, and participates in research grants for Amgen, Eli Lilly, Merck, Novartis, sanofi-aventis, and Takeda.

Curatio CME Institute
Shari J. Dermer, PhD
Director, Scientific Services
Exton, Pennsylvania

Jonathan S. Simmons, ELS
Managing Editor
Exton, Pennsylvania

Dr. Dermer and Mr. Simmons have no relevant financial relationships to disclose.

National Osteoporosis Foundation
Susan Randall, RN, MSN, FNP-BC
Senior Director, Science and Education
Washington, DC

Audrey Shively, MSHSE, CHES
Manager, Research and Professional Education
Washington, DC

Ms. Randall and Ms. Shively have no relevant financial relationships to disclose.

Review Committee Disclosure

In accordance with PCN policy, all content is reviewed by external independent peer reviewers for balance, objectivity, and commercial bias.  The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.

Unlabeled Use Declaration

During their presentation(s), faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

 

 

Select one of the two options to begin your CME activity.

 

 

 

 

 

This activity has expired and is no longer available for CME; however, we hope you still enjoy the education.

 

Attachments

Osteoporosis Bibliography

Osteoporosis Generic to Brand Name Table